<DOC>
	<DOCNO>NCT01363752</DOCNO>
	<brief_summary>The purpose study compare effect two anti-rejection therapy regimens kidney function kidney transplant recipient .</brief_summary>
	<brief_title>A Study Looking Kidney Function Kidney Transplant Recipients Who Are Taking Anti-rejection Medication Including Tacrolimus With Without Sirolimus .</brief_title>
	<detailed_description>This study evaluate potential reduce nephrotoxic calcineurin inhibitor ( CNI ) therapy lower tacrolimus exposure Advagraf® combination non-nephrotoxic immunosuppressant sirolimus avoid risk acute graft rejection , compare Advagraf® Mycophenolate Mofetil ( MMF ) immunosuppressive regimen .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>End stage kidney disease suitable candidate primary renal transplantation retransplantation ( unless graft lose rejection within 6 month ) Receiving kidney transplant decease living ( non Human Leukocyte Antigen [ HLA ] identical ) donor compatible ABO blood type Female subject childbearing potential negative serum urine pregnancy test enrollment Female male subject agree maintain highly effective birth control study 90 day discontinuation dose study drug . A highly effective method birth control define result low failure rate ( CPMP/ ICH/ 286/ 95 modify ) less 1 % per year use consistently correctly implant , injectables , combine oral contraceptive , Intrauterine Devises ( IUDs ) , sexual abstinence vasectomize partner Receiving previously receive organ transplant kidney Cold ischemia time donor kidney &gt; 30 hour Panel Reactive Antibody ( PRA ) &gt; 20 % Receiving graft nonheartbeating donor Maastricht category 3 ( withdrawal support await cardiac arrest ) Significant liver disease , define continuously elevate SGPT/ ALT and/ SGOT/ AST and/ total bilirubin level ≥ 2 time upper value normal range investigational site receive graft hepatitis C B positive donor Requiring initial sequential parallel therapy immunosuppressive antibody preparation ( ) Requiring ongoing dose systemic immunosuppressive drug prior transplantation ( minimal level immunosuppression follow failure previous transplantation without nephrectomy ) Significant , uncontrolled concomitant infection and/ severe diarrhea , vomit , active upper gastrointestinal tract malabsorption active peptic ulcer Pregnant woman breastfeed mother Subject donor know HIV positive Known allergy intolerance tacrolimus , macrolide antibiotic , corticosteroid , sirolimus , MMF product excipients iodine Evidence malignant disease within last 5 year , include nonmalignant skin cancer Currently participate another clinical trial , and/ take investigational drug within 28 day prior enrollment Unlikely comply visit schedule protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Kidney</keyword>
	<keyword>Transplant</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Kidney Failure , Acute</keyword>
	<keyword>Advagraf</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Astagraf XL</keyword>
</DOC>